DigiCon

@if (isset(session()->get('doctor')['vCentralCode']))

Back

@else

@endif

EVALuating cUrrent practices and unmEt needS in patients with CKD – VALUES CKD

Doctor's details

@if (isset(session()->get('doctor')['vCentralCode']))

Name of Doctor *

@else

Name of Doctor *

@endif

Doctor’s Degree*

Age *

Gender *

Male Female

@if (isset(session()->get('doctor')['vCentralCode']))

Speciality *

@else

Speciality*

@endif @if (isset(session()->get('doctor')['vCentralCode']))

City*

@else

City*

@endif

What should be the level to eGFR to initiate SGLT2i in non - diabetic CKD? *

>60 mL/min/1.73m²

>45 mL/min/1.73m²

>30 mL/min/1.73m²

>15 mL/min/1.73m²

In your practice, at which stage of CKD would you consider initiating Finerenone? *

Early – Stage 1 and II

Moderate – Stage III and IV

At all stages from I to IV

Any Other

what % of your diabetic CKD patients are on SGLT2i? *

All

>50%

> 25-50%

<25%

In what % of your diabetic CKD patients would you choose to initiate Finerenone? *

All

>50%

> 25-50%

<25%

In your opinion co-prescription of non-steroidal MRA - Finerenone and SGLT2i in diabetic CKD patients would *

Offer additive benefits due to different mechanisms of action

Don’t see additional benefit of administering Finerenone and SGLT2i together

Finerenone and SGLT2i together may lead to safety concerns

Any Other

What % of patients who are on Finerenone are also on SGLT2i in your clinical practice? *

>20%

>40%

>60%

>80%

How often do you see hyperkalemia in patients receiving Finerenone in your practice? *

>50%

25 to % 50 %

10-25%

<10%

What are the common risk factors for hyperkalemia in patients with CKD? Please tick multiple options *

CKD stage >3

CKD stage >4

Heart failure

Usage of concomitant drug classes (ARBs/ACEi/MRAs/NSAIDs) that cause hyperkalemia

Any Other

At what level of potassium would you initiate treatment for hyperkalemia in hospital setting? *

>5.5

>6.5

Only if patient is symptomatic

How many hyperkalemia patients receive calcium polystyrene sulfonate in your practice? *

<10 %

20-30%

40-50%

>50%

In what percentage of your patients with hyperkalemia and for what duration of time do you consider calcium polystyrene sulfonate? *

2-4 days	%
7 days	%
15 days	%
30 days	%
> 30 days	%

What is the treatment for hyperkalemia in emergency setting? *

What is the current need – gaps in therapy for the management of hyperkalemia in India *

How many patients; are on 4 pillars of diabetic CKD management (RAAS, SGLT2i, Finerenone & GLP-1) in your clinical practice? *

<5%

5-10%

11-20%

>20%

>50%

what is your preferred choice for initiating 4 pillars of management in diabetic CKD patients? *

All Together

Sequential

Depending upon the patients profile

Based on eGFR level

For the management of anemia in non-dialysis CKD, how many patients’ are on oral therapy of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor *

<10%

10-20%

20-40%

>50%

In your opinion how would you rate the following advantages of a HIF PH inhibitor (from 1-5, 1 – least important, 5 – most important)*

Adequate rise in Hb levels
Helps in better iron absorption in CKD patients
No need to give ESAs injections
Useful in patients who are less-responsive to ESAs
Helps to reduce requirement of Iron injections
Better tolerance as compared to ESAs

Do you prescribe HIF PH inhibitor – Desidustat in anaemia associated with chronic kidney disease? *

Yes

What proportion of thepatients whom you prescribe desidustat are dialysis dependent CKD? *

>25%

>50%

>75%

<10%

How long do you continue treatment with Desidustat in non-dialysis patients with anaemia associated with chronic kidney disease and monitor them? *

What are the causes other than diabetes for CKD do you frequently notice in your patients? (Please provide at least 3) *

In view of recent evidences on benefits of SGLT2i in non-diabetic CKD, in what % of your non- diabetic CKD patients are receiving SGLT2i? *

All

>50%

> 25-50%

<25%

How many patients of IgA nephropathy do you see in 1 month? *

1-2 patients

3-5 patients

6-10 patients

Currently how often do you consider dapagliflozin in the management of IgA nephropathy to lower proteinuria? *

> 50% of patients

> 30% of patients

>20% of patients

< 20% of patients

Kindly provide the benefits of dapagliflozin in patients with IgA nephropathy? *

How many CKD patients are with resistant hypertension in your clinical practice? *

<10%

10-20%

20-30%

>30%

30-40%

In your patients with resistant hypertension – how often would you consider a non-steroidal MRA *

> 50%

>30%

>20%

<10%

Please provide management strategy of resistant hypertension in patients already on at least 3 classes of drugs including diuretic in your clinical practice? *

Please provide management strategy for metabolic acidosis due to chronic kidney disease? *

Please provide management strategy for chronic kidney disease -Mineral Bone Disorder (CKD- MBD)? *

In secondary prevention of cardiovascular diseases among CKD patients which is your preferred regimen? *

Statins

Statins + Low Dose Aspirin

Statins + Low dose Aspirin + Non-Vitamin K Antagonist Oral Anticoagulants

Any Other